CTRI/2022/01/039859尚未招募未知
A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of OLNP-27 versus placebo in Reducing Symptoms of Knee Osteoarthritis
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and female subjects 40 to 75 years of age
- •Unilateral or bilateral OA of the knee for greater than 3 months (ACR criteria)
- •Subjects with radio graphic evidence by Kellgren - Lawrence grade 2 or 3
- •Female subjects of childbearing potential must be using a medically acceptable form of birth control. Female subjects of non-childbearing potential must be amenorrheic for at least 1 year or had a hysterectomy and/or bilateral oophorectomy
- •VAS score during the most painful knee movement between 40-70 mm
- •Subjects having mild-to-moderate pain not adequately or completely controlled with anti-inflammatory drugs
- •Results of screening are within normal range or considered not clinically significant by the Principal Investigator
- •Drug naive subjects for OA treatment or subjects willing to refrain from using ibuprofen, aspirin or other NSAIDS (other than acetaminophen/paracetamol as rescue) or any other pain reliever including topical application (OTC or prescription) and Omega 3 fatty acids during the entire trial
- •Willing to sign the informed consent and comply with study procedure
排除标准
- •Female subjects, who are pregnant, breast feeding or planning to become pregnant
- •Subject has known allergy to non-steroidal anti-inflammatory drugs (NSAIDs) (including aspirin) or has a suspected hypersensitivity, allergy or other contraindication to any compound present in the study medication
- •History of underlying inflammatory arthropathy or severe RA or OA
- •Subjects scheduled for any surgery within 3 months of completing the study
- •Recent injury in the area affected by OA of the knee (past 4 months)
- •History of Gout
- •History of congestive heart failure
- •Evidence or history of clinically significant (in the judgment of the Investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, or malignancies
- •History of Systemic Lupus Erythematosus (SLE)
- •High alcohol intake ( >2 standard drinks per day) or use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc)
- •History of psychiatric disorder that may impair the ability of subjects to provide written informed consent
- •Participation in any other trials involving investigational or marketed products within 30days prior to the Screening Visit
- •Have taken any corticosteroid, indomethacin, glucosamine + chondroitin, within 3 months prior to the Treatment Period, Day 0 (Visit 1) or intra-articular treatment / injections with corticosteroid or hyaluronic acid or Omega-3 Fatty acids dietary supplements within 6 months preceding the treatment period
研究者
相似试验
已完成
3 期
I4V-MC-JAIASystemic Lupus ErythematosusJPRN-jRCT2080224034Eli Lilly Japan K.K.750
招募中
3 期
A Study of 2 Doses of MAP0010 and Placebo in Asthmatic ChildreCTRI/2011/091/000069MAP Pharmaceuticals, Inc.360
尚未招募
不适用
A Clinical Study to Evaluate the Efficacy and Safety of OLNP-06 versus Placebo in Subjects with Primary DysmenorrheaCTRI/2022/02/039897Olene Life Sciences Private Limited
尚未招募
3 期
Efficacy and Safety evaluation of OLNP-06 in Subjects with Functional Dyspepsia.CTRI/2019/09/021019Olene Life Sciences Private Limited
进行中（未招募）
3 期
Phase III Study to Compare the Efficacy and Safety of Acotiamide 100 mg Tablets with Placebo in Patients with Functional Dyspepsia.CTRI/2015/02/005557PIN Limited222